An scAAV9 encoding SMN1, and designated Zolgensma®®, or onasemnogene abeparvovec-xioi, was FDA approved in 2019 for treatment of SMA as a one-time IV administration of 1.1 × 1014 vg/kg of [994]. The gene discussed is SMN1; the disease is proximal spinal muscular atrophy.